Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 3/20 | 0.42 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917355 | 1.00 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2CSNK1ESIRT2 | |
| SCHEMBL2910314 | 0.89 | CSNK1E (0.48) | NPC1RAB9ASMN1; SMN2CSNK1ETLR2 | |
| SCHEMBL2915216 | 0.89 | CSNK1E (0.48) | NPC1RAB9ASMN1; SMN2CSNK1ETLR2 | |
| SCHEMBL2913807 | 0.88 | MMP3 (0.48) | CSNK1EMMP3MMP8MMP9MMP1 | |
| SCHEMBL8780190 | 0.81 | SIRT2 (0.44) | CSNK1ESIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL5159604 | 0.80 | CSNK1E (0.51) | NPC1RAB9ASMN1; SMN2CSNK1ETLR2 | |
| SCHEMBL20185592 | 0.80 | SMN1; SMN2 (0.43) | NPC1SMN1; SMN2LMNA | |
| SCHEMBL6026038 | 0.80 | CSNK1E (0.49) | NPC1RAB9ASMN1; SMN2CSNK1ETLR2 | |
| SCHEMBL3429104 | 0.80 | CSNK1E (0.49) | NPC1RAB9ASMN1; SMN2CSNK1ETLR2 | |
| SCHEMBL22749478 | 0.80 | CSNK1E (0.49) | NPC1RAB9ASMN1; SMN2CSNK1ETLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751126-B1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1751126-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-7074822-B2 | Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005080366-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | PNLIP, CEL, LIPE | NPC1 1236/4885RAB9A 1363/4885SMN1; SMN2 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.